Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotech
1 year chart
1 day chart
ImmuPharma PLC

ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

ImmuPharma's license partner begins recruitment for Lupuzor trial for US FDA evaluation

23rd Jun 2010, 11:25 am by Sergei Balashov
ImmuPharma's license partner begins recruitment for Lupuzor trial for US FDA evaluation

Specialist drug discovery and development company ImmuPharma (LON:IMM) has announced that Cephalon (NASDAQ:CEPH), its license partner for IPP-201101 Rigerimod (Lupozor), has started the recruitment of lupus patients for a Phase IIb trial in the US.

The study is designed to allow US based investigators and the FDA (Food and Drugs Administration) to evaluate its lead candidate for the treatment of lupus before commencing a Phase III clinical trial, the results pf which will be part of the package to be submitted to the FDA and other regulatory authorities for approval.

Cephalon has also entered into a separate sub-license agreement with Symbio Pharmaceuticals, retaining all commercialisation rights to Lupuzor in Japan, while Symbio is granted an exclusive right to conduct a Japanese-based Phase I clinical study which is mandatory for a future filing of the drug with the country’s regulatory bodies. The agreement is aimed at preparing for the commercial development of Lupuzor in Japan.

“We are extremely encouraged with the progress Cephalon is making with regards to the US trials, first steps into Japan and importantly their commitment to the Lupuzor programme,” said chief executive of ImmuPharma Dimitri Dimitriou.

ImmuPharma licensed Lupuzor to Cephalon last year for milestone payments that could reach US$500 million with US$45 million received so far, including US$15 million in Q4 and US$30 million in 2009. Final results of the Phase IIb study of the drug showed a clinically significant improvement in patient response rate versus placebo.

ImmuPharma is currently involved in the development of five drug candidates, which it claims have significant sales potential, for the treatment of: lupus; cancer; moderate to severe cancer pain or post-operative pain; highly resistant, hospital-acquired infections such as MRSA; and inflammatory and allergic disorders.

No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here